Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 34.25
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell